Neuromelanin-Sensitive MRI as Candidate Marker for Treatment Resistance in First-Episode Schizophrenia

CONCLUSIONS: These findings provide further evidence for dopaminergic differences between medication responders and nonresponders and support the potential of NM-MRI as a clinically applicable marker for treatment resistance in schizophrenia.PMID:38476044 | DOI:10.1176/appi.ajp.20220780

Source: The American Journal of Psychiatry - March 13, 2024 Category: Psychiatry Authors: Marieke van der Pluijm Kenneth Wengler Pascalle N Reijers Clifford M Cassidy Kaithlyn Tjong Tjin Joe Olav R de Peuter Guillermo Horga Jan Booij Lieuwe de Haan Elsmarieke van de Giessen Source Type: research